

## Teplizumab: Adis Evaluation

### Key Points

- A CD3-directed monoclonal antibody (humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of T1D
- Received its first approval on 17 November 2022 in the USA
- Approved to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years of age and older with Stage 2 T1D

### Summary

Teplizumab (teplizumab-mzwv; TZIELD™) is a CD3-directed monoclonal antibody (humanized IgG1κ) that is being developed by Provention Bio, Inc. for the treatment of type 1 diabetes (T1D).

In November 2022, teplizumab was approved in the USA to delay the onset of Stage 3 T1D in adults and pediatric patients 8 years of age and older with Stage 2 T1D, based on results of a clinical trial in high-risk relatives of individuals with T1D.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.